Jonathan T. Silverstein, JD, is a general partner of OrbiMed, a healthcare-focused investment company. Mr. Silverstein joined OrbiMed in 1998 to focus on private equity and structured transaction in small capitalization public biotechnology and medical device companies. Mr. Silverstein was previously a director of life sciences in the Investment Banking Department at Sumitomo Bank, and an associate at Hambro Resource Development. Mr. Silverstein holds a JD and MBA from the University of San Diego, and a BA in economics from Denison University. Currently, Mr. Silverstein is the chairman of two companies Enobia and Cerapedics, and a director of three companies, SuperDimension, Glaukos, and NxStage Medical (NXTM). He has been a director or observer in more than a dozen companies including: LifeCell (LIFC), Given Imaging (GIVN), Cerexa (sold to Forest Labs), Peninsula Pharmaceuticals (sold to JNJ), Predix (sold to EPIX), Avanir (AVNR), Orthovita (VITA), Auxillium (AUXL), Bioenvision (sold to Genzyme), Adiana (sold to Cytyc), and Adolor (ADLR).


Price Data
NASDAQROKA